Drug Trial Radar · NCT04974008
Osteosarcoma Maintenance Therapy With OST31-164
Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
39
Actual
Start
Oct 21, 2021
Primary completion
Sep 21, 2023
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- Emerald Clinical Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.
Conditions
- Bone Cancer
Interventions
OST31-164Drug
Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free SurvivalTime frame: Every 3 months, up to one year
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente Downey Medical Center
Los Angeles, California
Children's Hospital of Orange County
Orange, California
Rady Children's Hospital
San Diego, California
Children's Hospital of Colorado
Aurora, Colorado
Connecticut Children's
Hartford, Connecticut
Nemours/ Alfred I duPont Hospital for Children
Wilmington, Delaware
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Children's Healthcare of Atlanta
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Johns Hopkins Medical Center
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Montefiore Medical Center
The Bronx, New York
Nationwide Children's Hospital
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
UT Southwestern Medical Center
Dallas, Texas
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.